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Glomerulopathy with fibronectin (FN) deposits (GFND) is an auto-
somal dominant disease with age-related penetrance, character-
ized by proteinuria, microscopic hematuria, hypertension, and
massive glomerular deposits of FN that lead to end-stage renal
failure. The genetic abnormality underlying GFND was still un-
known. We hypothesized that mutations in FN1, which encodes FN,
were the cause of GFND. In a large Italian pedigree with eight
affected subjects, we found linkage with GFND at the FN1 locus at
2q32. We sequenced the FN1 in 15 unrelated pedigrees and found
three heterozygous missense mutations, the W1925R, L1974R, and
Y973C, that cosegregated with the disease in six pedigrees. The
mutations affected two domains of FN (Hep-II domain for the
W1925R and the L1974R, and Hep-III domain for the Y973C) that
play key roles in FN–cell interaction and in FN fibrillogenesis.
Mutant recombinant Hep-II fragments were expressed, and func-
tional studies revealed a lower binding to heparin and to endo-
thelial cells and podocytes compared with wild-type Hep-II and an
impaired capability to induce endothelial cell spreading and cy-
toskeletal reorganization. Overall dominant mutations in FN1 ac-
counted for 40% of cases of GFND in our study group. These
findings may help understanding the pathogenesis of proteinuria
and glomerular FN deposits in GFND and possibly in more common
renal diseases such as diabetic nephropathy, IgA nephropathy, and
lupus nephritis. To our knowledge no FN1 mutation causing a
human disease was previously reported.
genetics  proteinuria  extracellular matrix  kidney  podocytes
G lomerulopathy with fibronectin (FN) deposits (GFND) is ahereditary kidney disease (MIM 601894) with proteinuria,
microscopic hematuria, and hypertension that lead to end-stage
renal failure (ESRF) in the second to sixth decade of life. The
condition was recognized as a distinct disease entity by Strom et
al. (1). Light microscopy demonstrated enlarged glomeruli with
deposits in the mesangium and subendothelial space, with scant
immunoreactivity for immunoglobulins or complement factors
(1). The most striking finding in this disease is strong immune
reactivity of the glomerular deposits to FN (1), an adhesive
high-molecular-weight dimeric glycoprotein that is part of ex-
tracellular matrix (2).
Clustering of the disease within families (1, 3) indicates a
genetic origin for GFND, and segregation is consistent with an
autosomal dominant pattern of inheritance with age-related
penetrance. However, the genetic abnormality underlying
GFND was still unknown (3–5). By whole-genome linkage
analysis in a large pedigree, a gene locus for GFND was mapped
on 1q32, within a 4.1-cM interval that contains a cluster of genes
involved in the regulation of complement activation (RCA) (6).
However, mutational analysis and functional studies failed to
find any abnormality (7).
Here, we investigated the genetic basis of GFND. Results of
linkage analysis excluded the 1q32 locus and revealed a region
on 2q34 containing the FN1 gene, encoding FN, as a previously
undescribed locus for the disease. By sequence analysis, we
found heterozygous FN1 mutations that cosegregate with the
disease in six of 15 unrelated pedigrees. We studied the molec-
ular implications of the genetic defects to the pathogenesis of
proteinuria and FN glomerular deposits in GFND.
Results and Discussion
Studies in Pedigree F233. Clinical description. This is an Italian family
that has been partially described (1) and was updated in the
present paper. Overall, eight subjects in this pedigree [three
previously described (1) and five newly reported in this paper]
were affected by the disease in accordance with the criteria
described in Methods. Five of them underwent renal biopsy
showing enlarged glomeruli with extensive deposits in the mes-
angium and subendothelial space that stained very strongly for
FN. FN was mainly stained by an antibody detecting both plasma
and cell-derived FN and to much lesser degree by an antibody
specific for only cell-FN (8), suggesting that the FN that accu-
mulated in the glomeruli wasmainly derived from the plasma (9).
By electron microscopy, the deposits were mainly granular (1, 8).
The clinical course of the affected subjects is shown in Table
1. The index case, subject 717, is a 14-year-old boy who was
referred in 2005 to the Department of Nephrology of Ospedali
Riuniti di Bergamo with nephrotic-range proteinuria (7.46 g per
day), low serum albumin, and severe hypertension. He received
a multidrug treatment titrated against urinary protein excretion
[see supporting information (SI) Text] and after 2 years, urinary
protein excretion is about one-third the baseline values, blood
pressure is completely normalized, and the renal function is
stably normal (Table 1).
Three of the other affected subjects (716, 723, and 725)
developed ESRF, and two of them (716 and 723) received a renal
transplant. Three years after transplantation, an allograft biopsy
in subject 716 showed recurrence of the disease in the transplant
(Table 1). In subject 723, the graft was functioning well at 1 year
follow-up.
Identification of a locus for GFND.We performed haplotype analysis
in pedigree F233 by using 10 polymorphic microsatellite DNA
markers spanning 22Mb along the RCA cluster at the 1q32 locus
(6) (see SI Text and SI Fig. 4).
Seventeen subjects were haplotyped. Segregation of GFND in
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this family was consistent with autosomal dominant inheritance
and age-related penetrance. Because the disease has progressive
manifestations, the absence of the disease could not be deter-
mined with certainty in the four healthy subjects of the third
generation (all 35 years of age). Data were first evaluated on
the basis of ‘‘affecteds-only’’ strategy. None of the haplotypes
cosegregated with GFND and linkage analysis by GENE-
HUNTER software gave a multipoint logarithm of odds (lod)
score less than2 throughout the chromosomal area. In further
analyses, liability classes were assigned according to age at
examination, as described in Methods. Results of two-point and
multipoint linkage analyses confirmed the exclusion of 1q32 as
disease locus in this pedigree (SI Fig. 4).
We further performed haplotype analysis on loci including
genes encoding other proteins of the complement system,
namely complement factor D (CFD) and complement C3
(19p13) and CD59 (11p13), with negative results in both regions
(data not shown).
We then looked at the locus of the candidate gene FN1 at
2q34, because FN1 encodes FN, the main component of glo-
merular deposits in GFND. Eighteen subjects (including the
deceased subject for whom DNA was obtained from autopsy
material) were haplotyped in a 37-Mb interval between markers
D2S2167 and D2S2297 (Fig. 1a). All subjects affected with
GFND shared the same haplotype, and none of the unaffected
subjects inherited this allele except for subject 733 in the third
generation that was unaffected at the time of analysis but was still
at risk because of the young age (24 years). Of note, subject 733
had a mild progressively worsening proteinuria (from 0.18 g per
24 h in 2006 to 0.30 g per 24 h in 2007) but normal renal function.
Recombination events were found between markers D2S2387
and D2S2289 in the second generation and between markers
D2S2359 andD2S2297 in the third generation (Fig. 1a). With the
affecteds-only model, linkage analysis gave a maximum multi-
point lod score of 1.8. Two-point linkage analysis with liability
classes (see Methods) resulted in Zmax  3.084 (  0) for
markers D2S128 and D2S2361, which is very close to maximum
values obtained with SLink simulation (SI Table 2). Consistently,
multipoint linkage analysis with the eight microsatellite markers
gave a Zmax plateau of 3.084 on the same markers (Fig. 1a).
Identification of an FN1 mutation. We sequenced the exons and
flanking intronic regions of FN1 (NC000002, gi:51511462). A
list of primers used for sequencing is given in SI Table 3.
A heterozygous 5773TA missense mutation in exon 36,
which causes a tryptophan-to-arginine substitution (W1925R) in
the III13 repeat (Fig. 1 b and c), was identified in all affecteds and
in subject 733 (Fig. 1a) and was not found in the other nine
subjects of the pedigree or in any of 100 healthy subjects.
We then screened FN1 in 14 additional GFND pedigrees and
FN1 mutations were found in five of them, as reported below.
Studies in Pedigree F656. The family is from New Zealand with six
affected subjects, the father and five of seven siblings. FN
deposition was confirmed by biopsy in four cases. The affected
children presented with proteinuria at a wide age range of 14, 16,
26, 43, and 47 years, respectively. Three patients developed
ESRF at ages 33, 34, and 35 years and received either successful
renal transplantation (two cases) or hemodialysis. Sequencing of
FN1 revealed a heterozygous missense mutation (5921TG) in
exon 37 in the affecteds, leading to an L1974R change in repeat
III13 (Fig. 1 b and c). The mutation segregated with the affected
status and was not found in the mother, the two healthy siblings
and 180 healthy control individuals.
Studies in Pedigree F468. This is an Italian family previously
described (1, 8) with three affected subjects. The proband is a
53-year-old woman who developed proteinuria in the nephrotic
range at 25 years of age. Presently, proteinuria is still in the
nephrotic range, and renal function is moderately reduced. Her
daughter developed nephrotic range proteinuria at 14 years of
age (1, 8). Presently, at the age of 25 years, renal function is
normal. In both affected subjects, biopsy confirmed diagnosis of
Table 1. Clinical data from GFND affected subjects of pedigree F233
Patient
sex/age*
Data at first observation Followup Data at last observation
Age,
yr
Proteinuria,
g/24 hr
S. creat.,
mg/dl
Hypert./
microh.
Age at
N-range
proteinuria
Age at
hypert./microh.
Age at
ESRF
Age at
TR
Age,
yr
Proteinuria
g/24 h
S. creat.,
mg/dl
Hypert./
microh.
725‡ 59 Nephrotic range Normal /? 59 59/? 74 — 73† 2.5† 4.0† /?†
F/77
719 44 300 mg/dl 1.4 /? 46 46/46 — — 54 1.06 1.55 /
M/55
Died‡ 40 ? 2.2 /? — 40/? — — — — — —
M
720 35 Nephrotic range 1.5 /? 35 35/— — — 46 1.42 2.52 /
M/48
716‡
M/42
18 4.16 1.4 / 18 19/— 32 37 41 0.2¶ 1.22¶ /
721 27 0.74 0.8 / — —/27 — — 40 4.77 1.0 /
M/40 (Normal)
723‡ 16 ? Normal /? 24 30/? 34 35 35 ? 1.5¶ ?
M/39
717‡ 12 7.46 0.7 / 12 12/12 — — 14§ 2.31§ 0.7§ /§
M/14 (Normal)
Nephrotic range (N-range) proteinuria:3.5 g per 24 h, S. creat, serum creatinine; normal values, 0.6–1.3 mg/dl; died, deceased at the age of 47 years because
of rupture of subarachnoid aneurysm; —, not applicable.
*Age at present.
†Data before ESRF.
‡Biopsy diagnosis.
§Values recorded after 2 years of multidrug renoprotective treatment.
¶Measured after kidney transplantation.
Castelletti et al. PNAS  February 19, 2008  vol. 105  no. 7  2539
G
EN
ET
IC
S
GFND, and electron microscopy examination revealed mainly
granular deposits in the subendothelial space and in the mes-
angium with few fibrils. A paternal aunt of the proband died at
37 years of age of nephropathy. The proband’s father died of
cancer at 30 years of age.
A heterozygous 2918AG mutation causing a Y973C change
in repeat III4 was found in the index case and in her affected
daughter but not in the unaffected father (Fig. 1 b and c and SI
Fig. 5) or in any of 230 healthy Caucasian controls.
Studies in Pedigree F546. The family is from The Netherlands and
includes two affected subjects (10). The index case is a male who
developed low-grade proteinuria at 29 years of age. At 38 years,
proteinuria was in the nephrotic range, and a renal biopsy
revealed GFND. In his first child, proteinuria (2.8 g per 24 h) was
detected at the age of 21 years. Renal biopsy showed glomerular
lesions similar to those seen in his father with massive deposits
in the mesangial area and to a lesser extent in the subendothe-
lium (10) that showed a fine granular pattern alternating with
areas containing more regularly arranged fibrils. Immunofluo-
rescence showed strong staining for plasma FN (10). At the last
update, the other son, 21 years old, was healthy.
The heterozygous 2918AG mutation was found in the index
case and in the two sons (Fig. 1 b and c, and SI Fig. 5). Because
of the age-related penetrance of GFND, the unaffected son can
be considered still at risk.
Studies in Pedigree F663. In a German pedigree with four affected
siblings, biopsies in two cases confirmed the diagnosis of GFND.
Proteinuria was observed in all four cases. One patient (pro-
teinuria at 18 years of age) developed ESRF at 33 years. In the
oldest patient (42 years), serum creatinine levels are in the range
2–3 mg/dl.
The heterozygous 2918AG mutation was found in all four
affected siblings but not in the unaffected mother (Fig. 1 b and
c and SI Fig. 5). DNA from the father was unavailable (deceased,
cause unknown), thus we could not establish the origin of the
mutation.
Studies in Pedigree F1098.The family is from Japan (11). The index
case is a boy who developed high-grade proteinuria and micro-
scopic hematuria at the age of 3 years. Renal biopsy revealed
enlarged glomeruli with deposition of granular material in
glomeruli that stained brightly with anti-FN antibodies (11).
Family history was remarkable for renal disease in 12 members
that hadmild hematuria and/or proteinuria but neither nephrotic
syndrome nor renal insufficiency. No relative had undergone
renal biopsy (11). It was hypothesized that the index case has a
different disease than anybody in this pedigree that segregates a
mild nephropathy (11).
The heterozygous 2918AG mutation was found in the index
case but not in any of nine subjects in this family. Specifically, the
mutation was not found in the mother or in any of the other three
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Fig. 1. FN1 mutations in GFND. (a) (Upper) Haplotype analysis at FN1 locus in pedigree F233. Microsatellite loci are on the left. (Lower) Multipoint linkage
analysis by GENEHUNTER (model: autosomal dominant transmission with age-related penetrance, analysis with liability classes). For markers D1S128 and
D1S2361, the maximum lod score was Zmax  3.084, as indicated. *, subjects previously published. ‡, biopsy-proven GFND. Solid symbols, affected individuals;
crossed symbols, deceased; violet arrow, proband: the whole FN1was sequenced; red dots, FN1mutation carriers. ¶, subjects screened for the FN1mutation and
for SNP segregation; un, unavailable. (b) Schematic diagram of fibronectin. Fibronectin monomer consists of type I (blue), II (green), and III (orange) repeats and
the alternatively spliced sites EDI, EDII, and IIICS. The three main heparin-binding domains and the binding sites for integrins are shown. Positions of the
GFND-associated mutations are indicated by arrows. (c Upper) Pedigrees of the other five families with FN1mutations. (Lower) The number of affected subjects,
the mutation, and the origin of all of the six mutated families, are reported.
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siblings in either of the father’s two haplotypes (DNA from the
father was not available), indicating that it occurred de novo in
the proband (Fig. 1 b and c and SI Fig. 5).
Of note, the Y973C change was found in four pedigrees from
different ethnic backgrounds (Italy, The Netherlands, Germany,
and Japan; Fig. 1 b and c). Haplotype analysis in the four
pedigrees showed no haplotype sharing, making a common
founder origin very unlikely (SI Fig. 5).
Overall, we have studied 15 different families, including most
of the published (1, 8, 10, 11) and additional unpublished
pedigrees, six of which (40%) carried FN1 mutations. All
affected subjects carried the mutation, and segregation was
compatible with autosomal dominant inheritance (Fig. 1c). In
the six probands carrying FN1 mutations, we also found several
SNPs of which the nine coding SNPs and the two previously
undescribed intronic SNPs are reported in SI Table 2. Sequenc-
ing of family members for nonsynonomous SNPs revealed that
rs17449032 does not segregate with GFND, whereas rs1250259
segregated in families F468 and F546 (SI Table 4) but not in
family F233 (SI Fig. 6).
Partial protein sequence alignment among multiple species
showed that residues W1925, L1974, and Y973 are highly
conserved (SI Fig. 7). These findings provide evidence that
mutations in FN1 are responsible for GFND.
Functional Studies on GFND-Associated FN1Mutations.Fibronectin is
secreted in a dimeric form and plays a role in cell-matrix contact
processes such as cell attachment and spreading, cell migration,
control of cell cytoskeleton and morphology and differentiation
(9, 12, 13). It also participates in extracellular matrix formation,
hemostasis, and thrombosis (12). All of these biological activities
imply interaction of FN with cells and with extracellular material
via binding sites for integrins, heparin, and heparan-sulfate
proteoglycans.
Each FN monomer consists of homologous modules classified
as type I, II, or III repeats (Fig. 1b). The C-terminal III12–14
repeats (Hep-II) contain the main binding site for heparin (14,
15) and III13 accounts for98% of Hep-II activity. It comprises
a ‘‘cationic cradle’’ with six positively charged residues and a
hydrophobic core that consists of P1908, W1925, F1936, L1964,
and Y1970 (15, 16). The W1925R mutation introduces a basic
amino acid in the Hep-II hydrophobic core. Similarly, the
L1974R mutation introduces a basic amino acid very close to the
Hep-II hydrophobic core (Fig. 2a). The two mutations could
theoretically increase the Hep-II affinity for heparin, by provid-
ing additional cationic charge to the domain; however, they
could also alter the folding of the domain and impair its function.
To investigate the functional effects of the W1925R and
L1974R mutations on Hep-II binding to heparin and cells, we
generated III12–14wt , III12–14W1925R, and III12–14L1974R poly-His-tagged re-
combinant fragments and expressed them in Sf9 cells. Recom-
binant wild-type and mutant proteins were expressed and se-
creted by insect cells and were detected as a band of 34 kDa
on Western blot (Fig. 2 b and c). Wild-type and mutant proteins
gave a similar staining with the anti-His antibody, indicating they
were expressed at the same level. By contrast, a fainter staining
of the mutant proteins was observed with the anti-FN antibody,
which suggests that the mutations cause changes in epitope
recognition.
Binding of the III12–14
W1925R and the III12–14
L1974R purified recombi-
nants to immobilized heparin (by ELISA) showed a significative
(P  0.01) reduction in respect to the wild-type (Fig. 3A). As a
consequence, binding of the mutants to endothelial cells (human
dermal microvascular endothelial cells line, HMEC-1) and im-
mortalized mouse podocytes was strongly reduced (P  0.01 vs.
wild type), as documented by FACS and confocal microscopy
analysis (Fig. 3 B and C). Similar results were obtained with
human umbilical vein endothelial cells (HUVEC, SI Fig. 8).
The initial attachment and spreading of cells to FN is mediated
by the interaction of the RGD-containing domain in the FN
III9–10 repeats with 51 cell integrin (17). But further progres-
sion to the formation of actin stress-fibers and focal contacts
requires binding of Hep-II to cell-surface proteoglycans and inte-
grins (18–20). We therefore hypothesized that lower heparin af-
finity and cell binding of the III12–14
W1925R and III12–14
L1974R resulted in
impaired capability to trigger stress-fiber formation and cell
spreading. This possibility was tested in vitro in HMEC plated on
a layer of 120-kDa fragments of FN containing the RGD domain
but lacking the Hep-II domain, in the presence of the III12–14
recombinants (19) (Fig. 3D). HMEC plated on the 120-kDa
fragment were able to attach, however, they showed few actin
stress fibers, indicating they were not completely spread. If the
III12–14
wt was added to the media, the percent of stress fiber-
positive cells was enhanced 3-fold (19), whereas this increase did
not occur when either mutants were added at the same concen-
tration (P  0.01 vs. wild type; Fig. 3D).
The third GFND-associated mutation, Y973C, affects another
heparin-binding domain of FN, Hep-III, located in the III4–5
repeats. It shares with Hep-II the capability of promoting
stress-fiber and focal-adhesion formation (21). The Y973C mu-
tation introduces an additional cysteine in III4, which could
affect protein folding and function through the formation of
abnormal Cys–Cys bonds.
Pathogenetic Hypothesis. The above reported FN1mutations, and
their functional consequences could explain the severe protein-
uria and microscopic hematuria that precede progressive renal
disease in GFND. Indeed, disturbance in cell spreading and
cytoskeleton in glomerular endothelial cells and podocytes due
to impaired interaction with mutant FN, is expected to alter the
glomerular size-selectivity properties and induce abnormal pro-
tein trafficking (22, 23).
FN is present in plasma as a soluble form (pFN) or deposited
in extracellular matrix as insoluble organized fibrils (cellular FN)
(9). Renal biopsy specimens of GFND patients showed extensive
FN deposits in the mesangium and subendothelial space that are
mainly granular with only some admixture of irregularly ar-
ranged fibrils (1, 8, 10). By using specific antibodies for pFN and
cellular FN, it was documented that glomerular FN deposits are
mainly derived from plasma and to a lesser extent from resident
glomerular cells (1, 8, 10).
The Hep-II and -III domains play a main role in regulating FN
Fig. 2. Expression of recombinant wild-type and mutant Hep-II domains of
fibronectin. (a) Structure of FN III13. Amino acid residues are color marked for
positively charged (red), hydrophobic core (green), and residues W1925 and
L1974 (yellow). (b and c) WT and mutant purified recombinant proteins were
analyzed by SDS/PAGE on 12% gels and visualized by Western blotting with
either an antibody anti-His (C-term) (b) or an antifibronectin mAb against the
Hep-II domain. (c) Position of standards (kDa) are shown. Equal amounts (5g
each) of WT and mutant proteins were loaded. Separate lanes were labeled
with Coomassie blue as control for loading. Unt, untransfected.
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assembly into organized fibrils in extracellular matrix, through
complex FN–FN and FN–cell surface proteoglycan interactions
(18, 24–26). In addition, interaction between the Hep-II domain
and the III2–3 repeats keeps pFN in a compact soluble form
preventing its deposition in extracellular matrix (27). Based on
this evidence and on the results of functional studies presented
here, we suggest that GFND-associated mutations in FN1 impair
the control of the assembly of FN into fibrils and the balance
between soluble and insoluble FN, which could explain the
abnormal incorporation of nonfibrillary pFN in the glomerular
matrix that has been documented in renal biopsy specimens of
patients participating to the present study.
GFND is a very rare disease (1, 8, 10, 11, 28) however, the
present data may have implications for the understanding of the
pathogenesis of more common renal diseases characterized by
FN glomerular deposits, such as diabetic nephropathy (29), IgA
nephropathy (30), and lupus nephritis (31).
Methods
Patients and Diagnosis.We collected blood samples from all available affected
and nonaffected members of 15 pedigrees for isolation of genomic DNA after
informed consent. The definition of affected status was made on the basis of
either a renal biopsy or of a clinical history compatible with a GFND status
(with proteinuria, microhematuria, hypertension, and slowly decreasing renal
function), with at least one individual with biopsy proven GFND in each
pedigree (1). None of the affected subjects presented clinical or laboratory
evidence of systemic lupus, cryoglobulinemia, diabetes mellitus, amyloidosis,
or autoimmune disease. For the definition of absence of disease, the following
criteria were met: absence of significant proteinuria, of hematuria, normal
blood pressure, and normal renal function (6). All protocols included in these
studies have been approved by Institutional Review Boards. Informed written
consent was obtained from all participating subjects, according to the decla-
ration of Helsinki.
DNA Analysis. We performed linkage analysis in pedigree F233 on the candi-
date chromosomal region 1q32, 19p13, 11p13, and 2q34 (SI Text).
Haplotypes were reconstructed by using the GENEHUNTER package (Ver-
sion 1.2). Autosomal dominant transmission with age-related penetrance was
assumed on the basis of clinical and pedigree data (6). Liability classes were
assigned as follows: affected subjects and unaffected subjects of the first and
second generations were assigned liability class 1, with penetrance vector {0.0,
0.99, and 0.99}. Unaffected individuals in the third generation (all 35 years
of age) were assigned liability class 2, with penetrance vector {0.0, 0.50, and
0.75}. The disease gene frequency in the general population was set at 0.0001
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Fig. 3. Mutations in FN Hep-II domain cause reduced binding to heparin, endothelial cells, and podocytes and impair stress fiber formation. (A) Binding of III12–14
wt ,
III12–14
W1925R, and III12–14
L1974R to heparin by ELISA. O.D., optical density. (B and C) Binding of WT and mutant poli-His-tagged III12–14
W1925R and III12–14
L1974R recombinants added
to human endothelial cells (HMEC) and mouse podocytes (b) FACS analysis. (C) Confocal microscopy; original magnification,600). Staining was done with an
anti-His antibody plus FITC-conjugated (FACS) or Cy3-conjugated (confocal, red) secondary antibodies. MFI, median fluorescence intensity. (D) HMEC were plated
on a 120-kDa N-terminal FN fragment in the absence (a) or presence of III12–14
wt (b), III12–14
W1925R (c), III12–14
1974R (d), or full length FN (e), in serum-free medium for 3 h and
then labeled with rhodamine-phalloidin to visualize stress fibers. The percent of stress-positive cells (mean SD) is shown in the bottom (white numbers). Data
are mean  SD of three independent experiments. *, P  0.01 vs. WT. O.D. and MFI values were calculated after subtracting values recorded with addition of
buffer alone (blanks).
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(6). Two-point and multipoint linkage analyses were performed by GENE-
HUNTER by using both the affecteds-only and liability classes models. SLink
simulations were done by the FASTLINK package.
We sequenced the exons and the flanking intronic regions of FN1
(NC000002, gi:51511462). The gene has three regions subjected to alternative
splicing (EDI, EDII, and IIICS), with the potential to produce 20 different
transcript variants. We chose variant 1 that represents the longest transcript
and encodes the longest isoform (NM212482) (see SI Text and SI Table 3). The
amino acid numbering is referred to the translation start site (Met  1), and
the nucleotide number is referred to the A of the ATG start codon (www.ncbi.
nlm.nhi.gov, NM212482).
Expression and Functional Studies. The two mutations affecting the Hep-II
domain were introduced into human complementary DNA (cDNA) encoding
repeats III12–14 of FN and expressed as His-tagged fusion proteins in Sf9 cells by
the Baculovirus system (see SI Text).
Binding of wild-type and mutant III12–14 recombinants to heparin was
assessed by ELISA (32). The capability of wild-type and mutant III12–14 recom-
binants to bind endothelial cells (HMEC and HUVEC) and podocytes (immor-
talized mouse podocytes from Peter Mundel, Mount Sinai School of Medicine,
New York) (33) was evaluated by FACS and confocal microscopy analysis (see
SI Text) (34).
For spreading assays, HMEC cells were coated on glass coverslips previously
coated overnight with human 120-kDa FN alpha-chymotryptic fragment lack-
ing the Hep-II domain with or without purified wild-type III12–14 and mutant
III12–14
W1925R and III12–14
L1974R recombinant proteins. As positive control, cells were
seeded on glass coverslips coated with intact FN (19). At the end of the
incubation period, the F-actin filaments were stained with rhodamine-
phalloidin and cells were examined by using inverted confocal laser micros-
copy (see SI Text) (33).
Statistical Analysis. Data are reported as mean  SD. Results of functional
assays on wild-type and mutant III12–14 fragments of FN1 were compared by
Student’s t test for unpaired data.
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